Illumina Inc Stock Price, News & Analysis

Illumina (NASDAQ:ILMN) reported Q2 2025 financial results with revenue of $1.06 billion, marking a 3% decline from Q2 2024. The company achieved a GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8%, with GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19.

The company has revised its fiscal year 2025 guidance upward, now expecting total company constant currency revenue decline of (2.5%) to (0.5%), improved from previous guidance. Illumina also repurchased 4.5 million shares for $380 million during the quarter and announced plans to acquire SomaLogic from Standard BioTools, with the transaction expected to close in first half of 2026.

Despite challenging research funding conditions, Illumina reported strong performance in clinical segments and margin expansion, leading to increased yearly expectations. The company maintained $1.16 billion in cash and investments and generated $204 million in free cash flow for the quarter.

Illumina (NASDAQ:ILMN) has launched TruSight Oncology 500 version 2 (TSO 500 v2), an enhanced version of its flagship cancer research assay for comprehensive genomic profiling (CGP). The upgraded assay now includes built-in homologous recombination deficiency (HRD) detection at no additional cost, powered by Myriad Genetics' gold-standard Genomic Instability Scoring algorithm.

Key improvements include a streamlined workflow with reduced turnaround time, lower tissue sample requirements, and enhanced sustainability features including 50% less packaging and 70% fewer tubes. The assay enables comprehensive analysis of hundreds of genes and immuno-oncology biomarkers from small tissue samples to support cancer therapy research and clinical trial eligibility assessment.

Illumina (NASDAQ:ILMN) has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025, after market close. The company will host a conference call at 1:30 PM Pacific Time (4:30 PM Eastern Time) on the same day.

The earnings call will feature CEO Jacob Thaysen, PhD and CFO Ankur Dhingra, who will discuss the company's financial and operating results with analysts, investors, and other interested parties. Participants can access the live webcast through Illumina's Investor Info section or the provided registration link, and are advised to join ten minutes before the scheduled start time.

Illumina (NASDAQ: ILMN) has received two prestigious recognitions: inclusion in TIME's World's Most Sustainable Companies list for the second consecutive year and a spot on U.S. News & World Report's Best Companies to Work For list for the third consecutive year.

The company demonstrated strong environmental leadership with an 80% reduction in packaging since 2019 and maintained 100% renewable electricity consumption globally for three consecutive years. Their new MiSeq i100 Series sequencer features 85% less packaging and a 35% lower carbon footprint compared to the original system.

Illumina (NASDAQ: ILMN) has announced a definitive agreement to acquire SomaLogic from Standard BioTools for $350 million in cash, plus up to $75 million in performance-based milestones and royalties. The acquisition builds on their existing partnership since 2021 and aims to enhance Illumina's presence in the proteomics market while advancing their multiomics strategy. SomaLogic brings approximately 250 employees and facilities in Boulder, Colorado, including a CLIA- and CAP-certified lab. The deal combines SomaLogic's proteomics expertise with Illumina's NGS platforms, with the Illumina Protein Prep currently being used by 40 early-access customers globally. The transaction is expected to close in first half of 2026, subject to regulatory approvals, and become profitable by 2027 on a non-GAAP operating income basis.

Infinity Bio has secured $8 million in Series A financing led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. The company, which specializes in antibody reactome profiling, will use the funds to expand its commercial presence, enhance its MIPSA platform, and launch new immune profiling services. As part of its growth strategy, Infinity Bio has acquired Serimmune's assets and plans to launch new services including EnviroSIGHT in H2 2025. The company operates a 9,000 square-foot laboratory in Baltimore, offering services like HuSIGHT, VirSIGHT, AllerSIGHT, and MuSIGHT for biomarker discovery and research applications. The platform can process thousands of samples weekly, serving academic, government, and biopharma customers.

QIAGEN (QGEN) and Incyte (INCY) have announced a global collaboration to develop a novel diagnostic panel for myeloproliferative neoplasms (MPNs). The partnership focuses on creating a multimodal panel using next-generation sequencing technology to detect gene alterations in blood cancers, particularly targeting mutant calreticulin (mutCALR). The panel will support Incyte's drug portfolio, including INCA033989, and will be validated on Illumina's NextSeq 550Dx platform. QIAGEN will handle regulatory submissions and market access across the US, EU, and Asia-Pacific regions. The collaboration aims to improve treatment decisions for MPN patients, which represent about 40% of hematological malignancies, by enabling precise identification of genomic aberrations in biomarkers like CALR.

Illumina (NASDAQ: ILMN) has released its 2024 Corporate Social Responsibility Report, highlighting significant achievements in genomics accessibility and sustainability. The company expanded healthcare coverage for genomic testing to an additional 100 million people, reaching 1.4 billion lives covered. Notable sustainability achievements include an 80% reduction in packaging since 2019, exceeding their 2030 target, and maintaining 100% renewable electricity usage globally. The new MiSeq i100 Series launch demonstrated a 35% reduction in climate impact. Illumina reached 2.1 million STEM learners since 2019, maintained zero net pay gap for six years, and achieved a 45% decrease in scope 1 and 2 emissions from 2019. Employee engagement showed strong results with 52% participation in giving programs and over 91,000 volunteer hours contributed.

Illumina (NASDAQ: ILMN) has unveiled PromoterAI, a groundbreaking AI algorithm that accurately identifies pathogenic regulatory genetic variants in noncoding regions of the human genome. According to a study published in Science, this technology discovered regulatory variants in promoter segments that contribute up to 6% of genetic causes of rare diseases.

PromoterAI analyzes noncoding promoter regions, which are crucial for gene transcription and comprise over 98% of the genome. When combined with whole-genome sequencing (WGS), this AI tool could improve rare disease diagnosis rates, which currently stand at only 30% with exome sequencing. The algorithm, together with Illumina's other AI tools (PrimateAI-3D and SpliceAI), effectively doubles the diagnostic yield compared to using protein-truncating variants alone.

The technology is now available through Illumina Connected Software and DRAGEN™ secondary analysis, with precomputed scores freely available for academic and noncommercial research.